BTIG Assumes Nektar Therapeutics at Buy, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Robert Hazlett has assumed coverage of Nektar Therapeutics with a Buy rating and set a price target of $4.
September 30, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Robert Hazlett has assumed coverage of Nektar Therapeutics with a Buy rating and set a price target of $4.
The assumption of a Buy rating and a specific price target of $4 by a BTIG analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100